17. Enhanced Solubility of Poorly Soluble Drugs Via Spray Drying

  1. Dennis Douroumis1 and
  2. Alfred Fahr2
  1. Cordin Arpargaus,
  2. David Rütti and
  3. Marco Meuri

Published Online: 4 FEB 2013

DOI: 10.1002/9781118444726.ch17

Drug Delivery Strategies for Poorly Water-Soluble Drugs

Drug Delivery Strategies for Poorly Water-Soluble Drugs

How to Cite

Arpargaus, C., Rütti, D. and Meuri, M. (2013) Enhanced Solubility of Poorly Soluble Drugs Via Spray Drying, in Drug Delivery Strategies for Poorly Water-Soluble Drugs (eds D. Douroumis and A. Fahr), John Wiley & Sons Ltd, Oxford, UK. doi: 10.1002/9781118444726.ch17

Editor Information

  1. 1

    School of Science, University of Greenwich, UK

  2. 2

    Friedrich-Schiller University of Jena, Germany

Publication History

  1. Published Online: 4 FEB 2013
  2. Published Print: 21 JAN 2013

ISBN Information

Print ISBN: 9780470711972

Online ISBN: 9781118444726

SEARCH

Keywords:

  • Bioavailability;
  • Controlled drug release;
  • Drug delivery;
  • Encapsulation;
  • Evaporation;
  • Nanotechnology;
  • Particles;
  • Powders;
  • Scale-up;
  • Spray;
  • drying

Summary

Spray drying is a simple, rapid, reproducible, and scalable drying technique, allowing mild temperature conditions suited to heat-sensitive biopharmaceutical compounds. Compared to other methods used in drug delivery applications, spray drying is a continuous process to directly transform various liquids (solutions, emulsions, dispersions, slurries, pastes or even melts) into solid particles with adjustable size, distribution, shape, porosity, density, and chemical composition. In this chapter, numerous application examples are presented for the spray drying of poorly soluble drugs in the early stages of product development using a laboratory-scale spray dryer from BÜCHI Labortechnik AG.

Applications and spray drying process parameters are discussed in order to optimize:

  • • particle size to increase dissolution rates (e.g., improved controlled drug release profiles, better pharmacokinetic performance, and enhanced bioavailability);

  • • crystal habit modification (e.g., changing the morphological form of the solid from a crystalline structure to amorphous states);

  • • encapsulation of drugs in a suitable carrier or matrix (e.g., increase storage stability and protection of silica-lipid hybrid microcapsules, solid lipid nanoparticles as colloidal drug delivery systems, and microemulsions);

  • • conversion of nanosuspensions into flowable dry powders with high surface areas that can easily be redispersed;

  • • dry powder formulations for inhalation to treat asthma, cystic fibrosis, chronic pulmonary infections and lung cancers.